IntraBio Inc.’s drug for neurogenerative disorder gets US regulator’s nod
IntraBio Inc, a biotechnology company focused on rare and neurogenerative diseases, got the US regulator’s nod for a drug to treat a certain.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
IntraBio Inc, a biotechnology company focused on rare and neurogenerative diseases, got the US regulator’s nod for a drug to treat a certain.
HQ Team April 30, 2024: The Food and Drug Administration has cleared X4 Pharmaceutical’s drug to treat a rare genetic disease that occurs.